These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 24861285)

  • 1. Impact of the IL-18 gene polymorphism in response to antiviral therapy in chronic HCV genotype 4 patients.
    Mandour M; Nemr N; Kishk R; Ahmed E
    Rev Soc Bras Med Trop; 2014; 47(2):137-42. PubMed ID: 24861285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-10.rs1800896 and Interleukin-18.rs1946518 gene polymorphisms could not predict the outcome of hepatitis C virus infection in Egyptian patients treated with pegylated interferon plus ribavirin.
    Abdelraheem WM; Hassuna NA; Abuloyoun SM; Abdel Ghany HM; Rizk HA; Abdelwahab SF
    Arch Virol; 2016 Sep; 161(9):2473-80. PubMed ID: 27352267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of SNPs in interferon receptor genes in chronic hepatitis C with response to combined therapy of interferon and ribavirin.
    Heidari Z; Shahzamani K; Ghanbari R; Tahamsebifar A
    Acta Med Iran; 2014; 52(10):740-7. PubMed ID: 25369007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
    Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
    World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of cytokine gene polymorphism on histological activity index, viral load and response to treatment in patients with chronic hepatitis C genotype 3.
    Abbas Z; Moatter T; Hussainy A; Jafri W
    World J Gastroenterol; 2005 Nov; 11(42):6656-61. PubMed ID: 16425360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secreted Phosphoprotein 1 Promoter Genetic Variants Are Associated with the Response to Pegylated Interferon α Plus Ribavirin Combination Therapy in Egyptian Patients with Chronic Hepatitis C Virus Infection.
    Ali FT; Ali MA; Elgizawy MM; Elsawy AM
    Gut Liver; 2015 Jul; 9(4):516-24. PubMed ID: 25717047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic polymorphisms of ICAM 1 and IL28 as predictors of liver fibrosis severity and viral clearance in hepatitis C genotype 4.
    Rizk NM; Derbala MF
    Clin Res Hepatol Gastroenterol; 2013 Jun; 37(3):262-8. PubMed ID: 23137758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.
    Jabłonowska E; Piekarska A; Koślińska-Berkan E; Omulecka A; Szymańska B; Wójcik K
    Acta Biochim Pol; 2012; 59(3):333-7. PubMed ID: 22924160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-density lipoprotein receptor genetic polymorphism in chronic hepatitis C virus Egyptian patients affects treatment response.
    Naga M; Amin M; Algendy D; Elbadry A; Fawzi M; Foda A; Esmat S; Sabry D; Rashed L; Gabal S; Kamal M
    World J Gastroenterol; 2015 Oct; 21(39):11141-51. PubMed ID: 26494968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphisms in interleukin-10 and interleukin-28B genes in Egyptian patients with chronic hepatitis C virus genotype 4 and their effect on the response to pegylated interferon/ribavirin-therapy.
    Shaker OG; Sadik NA
    J Gastroenterol Hepatol; 2012 Dec; 27(12):1842-9. PubMed ID: 23020144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-nucleotide polymorphisms of IL-10 and IL-28B as predictors of the response of IFN therapy in HCV genotype 4-infected children.
    Shaker OG; Nassar YH; Nour ZA; El Raziky M
    J Pediatr Gastroenterol Nutr; 2013 Aug; 57(2):155-60. PubMed ID: 23880623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of
    Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
    World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Differential response to pegylated interferon plus ribavirin combination therapy in chronic hepatitis C and HIV/HCV co-infected patients].
    Liu B; Cai WP; Hu FY; Xu M; Lan Y; Tang XP
    Zhonghua Gan Zang Bing Za Zhi; 2013 Nov; 21(11):829-33. PubMed ID: 24331692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the frequency of the IL-28 polymorphism (rs8099917) in patients with chronic hepatitis C using Zip nucleic acid probes, Kerman, Southeast of Iran.
    Iranmanesh Z; Mollaie HR; Arabzadeh SA; Zahedi MJ; Fazlalipour M; Ebrahimi S
    Asian Pac J Cancer Prev; 2015; 16(5):1919-24. PubMed ID: 25773845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
    Aziz H; Raza A; Ali K; Khattak JZ; Irfan J; Gill ML
    Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single Nucleotide rs760370 Polymorphism at the Main Ribavirin Transporter Gene Detection by PCR-RFLP Assay Compared with the TaqMan Assay and Its Relation to Sustained Virological Response in Chronic HCV Patients Treated with Pegylated Interferon-Ribavirin Therapy.
    Fouad R; Zachariah K; Khairy M; Khorshied M; Ezzat W; Sheta MM; Heiba A
    J Interferon Cytokine Res; 2017 Feb; 37(2):90-96. PubMed ID: 28207300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endogenous IFNγ in chronic HCV genotype 4 patients treated with PEG-IFNα and ribavirin.
    Sadeq R; Mohtady H; Al Badawy N; Ibrahim S; Omar AR; Husseiny MI; El Zowalaty M
    J Infect Dev Ctries; 2013 Nov; 7(11):859-67. PubMed ID: 24240045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b.
    Yoshizawa K; Abe H; Aida Y; Ishiguro H; Ika M; Shimada N; Tsubota A; Aizawa Y
    J Med Virol; 2013 Jul; 85(7):1180-90. PubMed ID: 23918536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin.
    Selvapatt N; Habibi MS; Brown A
    J Med Virol; 2015 Oct; 87(10):1716-21. PubMed ID: 25914248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and safety of pegylated interferon α-2b injection (Y shape, 40 kD) in treatment of patients with genotype 1/6 chronic hepatitis C].
    Feng B; Shang J; Wu SH; Chen H; Han Y; Li YQ; Zhang DZ; Zhao LF; Wei SF; Mao Q; Yin CB; Han T; Wang MR; Chen SJ; Li J; Xie Q; Zhen Z; Gao ZL; Zhang YX; Gong GZ; Yang DL; Pan C; Sheng JF; Tang H; Ning Q; Shi GF; Niu JQ; Luo GH; Sun YT; You H; Wang GQ; Zhang LL; Peng J; Zhang Q; Liu JJ; Chen CW; Chen XY; Zhao W; Wang RH; Sun L; Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):187-194. PubMed ID: 28482405
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.